1. Home
  2. NNNN vs URGN Comparison

NNNN vs URGN Comparison

Compare NNNN & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Anbio Biotechnology Class A Ordinary Shares

NNNN

Anbio Biotechnology Class A Ordinary Shares

HOLD

Current Price

$16.79

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

HOLD

Current Price

$33.25

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NNNN
URGN
Founded
2021
2004
Country
Germany
United States
Employees
27
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.4B
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
NNNN
URGN
Price
$16.79
$33.25
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$29.29
AVG Volume (30 Days)
21.2K
569.0K
Earning Date
04-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,128,000.00
Revenue This Year
N/A
$129.09
Revenue Next Year
N/A
$70.96
P/E Ratio
$446.57
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.50
$12.73
52 Week High
$55.65
$33.40

Technical Indicators

Market Signals
Indicator
NNNN
URGN
Relative Strength Index (RSI) 33.36 71.52
Support Level $14.66 $18.58
Resistance Level $31.12 N/A
Average True Range (ATR) 3.11 1.67
MACD -0.97 0.40
Stochastic Oscillator 9.95 88.77

Price Performance

Historical Comparison
NNNN
URGN

About NNNN Anbio Biotechnology Class A Ordinary Shares

Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.

Share on Social Networks: